Guides

A "not for human consumption" label does not make an injectable peptide legal. We read four 2026 FDA warning letters to online peptide sellers and summarize what the agency looks at, and what it means for choosing a Houston clinic.

How often hair loss appeared in the FDA-approved labeling for Wegovy and Zepbound, what the Zepbound label says about weight reduction and sex differences, and when to bring it up with your prescriber.

Semaglutide is FDA-approved as Wegovy, Ozempic and Rybelsus, and a first generic has only tentative approval. Compounded semaglutide is a much narrower story. Current FDA status with sources and red flags.

Two clinics in the Galleria–Greenway–Tanglewood corridor pass PostDose's four-point standard today. What we confirmed about each prescriber, what the NPI registry does and doesn't show, and what to ask before you book.

Two free lookups — the federal NPI Registry for the prescriber and your state pharmacy board for the pharmacy — plus the FDA's warning signs for unsafe pharmacies. A practical checklist for any Houston GLP-1 clinic.

The exact missed-dose windows in the FDA-approved Wegovy and Zepbound labels (48 hours and 4 days), what the labels say about skipping several doses, and why compounded products need a conversation with your prescriber.

Tirzepatide is FDA-approved as Mounjaro and Zepbound — but 'compounded tirzepatide' is a different, much narrower legal story. Current FDA status with primary sources, and the red flags to check.

Two Heights-area clinics pass PostDose's four-point standard today. Here is what we confirmed about each prescriber, what the federal NPI registry does and doesn't show, and what to ask before you book.

The FDA's own alert on compounded semaglutide and tirzepatide lists specific, checkable red flags — fake pharmacy names, a 28-day rule for multi-dose vials, warm shipments, and dosing errors that sent patients to the hospital. Here's what it actually says.

How common nausea and vomiting really are on semaglutide and tirzepatide, what the FDA-approved labels say about dehydration, kidney injury, and pancreatitis, and how to tell ordinary dose-week queasiness from a reason to call your provider.

Ipamorelin has never had an FDA-approved drug application, and today it sits — unwithdrawn — on FDA's active list of compounding substances with significant safety risks. Here's the current status, with the primary sources.

Every clinic on this list passed PostDose's four-point verification standard: a named prescriber confirmed in the federal NPI registry, legal medication sourcing, a real address, and a public rating of 4.5 or higher.

We evaluated 2 GLP-1 and peptide clinics in Katy, TX. As of September 2026, neither currently passes our verification standard — here's exactly why, with primary sources and dates.

As of July 1, 2026, Medicare covers certain GLP-1 drugs for weight loss for the first time — through a temporary CMS demonstration, not a permanent Part D benefit. Here's exactly who qualifies, what it costs, and what it doesn't cover.

Why GLP-1 drugs cause constipation, what the FDA-approved labels actually say about ileus and intestinal obstruction, and why you need to tell your surgeon or dentist before any procedure with sedation.

Sermorelin's only FDA-approved product was discontinued for business reasons, not safety — and it isn't on any current FDA compounding list. Here's what that actually means, with the primary sources.

The FDA-approved label for Wegovy requires a real medical history screening before you ever get a prescription. Here's the exact list of questions a legitimate first appointment covers — and what it means if a clinic skips them.

Why GLP-1 patients lose their appetite after an injection, what the FDA label actually says about it, and how to eat through dose week without triggering nausea — sourced from the prescribing information, not a meal-plan blog.

BPC-157 was pulled from the FDA's compounding safety-risk list in 2026, then reviewed for a legal compounding pathway that still doesn't exist. Here's the current status, the source documents, and the red flags to watch for.

"Medical weight loss" is a marketing phrase, not a credential. Four checks — prescriber, medication sourcing, disqualifying programs, physical practice — that separate a legitimate Houston clinic from the rest, with the FDA rules behind each one.

The GLP-1 shortage that made bulk compounding legal is over. Here's what the FDA's own rules say about brand-name vs. compounded semaglutide and tirzepatide today, and the red flags we check for in every Houston clinic.